Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

BACKGROUND: Passive immunization against RSV (Respiratory Syncytial Virus) is given in most western countries (including Israel) to infants of high risk groups such as premature babies, and infants with Congenital Heart Disease or Congenital Lung Disease. However, immunoprophylaxis costs are extreme...

Descripción completa

Detalles Bibliográficos
Autores principales: Ginsberg, Gary M., Somekh, Eli, Schlesinger, Yechiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296113/
https://www.ncbi.nlm.nih.gov/pubmed/30554570
http://dx.doi.org/10.1186/s13584-018-0258-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296113/
https://www.ncbi.nlm.nih.gov/pubmed/30554570
http://dx.doi.org/10.1186/s13584-018-0258-4

Ejemplares similares